Carbon monoxide derived from the catalytic action of
heme oxygenase-1 or
carbon monoxide-releasing molecules (CORMs) has been found to potentially be an
anticoagulant or procoagulant agent. Of interest, two water-soluble CORMs, CORM-3 and
CORM-A1, recently became commercially available. Thus, the purpose of the present study was to assess and compare the effects of the previously well studied
CORM-2 to the effects of CORM-3 and
CORM-A1 on coagulation in citrated human plasma with thrombelastography. Plasma exposed to CORMs was incubated at 37°C for at least one
carbon monoxide release half-time, and then
tissue factor-activated coagulation was commenced with
calcium addition.
CORM-2 and CORM-3 enhanced the velocity of clot formation and
thrombus strength in a similar manner, whereas
CORM-A1 did not affect coagulation. However,
CORM-A1 did diminish
tissue-type plasminogen activator initiated fibrinolysis. The similarity in effect on coagulation by
CORM-2 and CORM-3 was likely secondary to the relatively inert effect of their
ruthenium-containing carrier molecule, whereas the
boron-containing
CORM-A1 may have had no effect secondary to
boron binding to
fibrinogen, preventing
carbon monoxide-mediated changes in
fibrinogen protein structure via attached
heme group(s). Future investigations with CORMs should have special attention to confounding effects of the carrier molecule.